Tempest Therapeutics, Inc.

NasdaqCM:TPST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 25.41 M

Share Price

USD 6.90

Avg Daily Volume

58,221

Change (1 day)

0.73%

Change (1 year)

Change (YTD)

-35.33%

Tempest Therapeutics, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2025

Tempest Therapeutics, Inc. Common Stock Issued is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Common stock issued is cash received from issuing new shares of the company’s common stock.

Tempest Therapeutics, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 7.50 M, a -78.46% change year over year.
Tempest Therapeutics, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 34.83 M, a -725.95% change year over year.
Tempest Therapeutics, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -5.56 M, a -117.17% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

NasdaqCM: TPST

Tempest Therapeutics, Inc.

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court
Employees	24
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.